Restricted drug distribution programs

American Journal of Health-System Pharmacy

Volumn 60, Issue 15, 2003, Pages 1525-1530

  Gabay, Michael P ^a   Costianis, Renee ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; DRUG;

DRUG INDUSTRY; DRUG INFORMATION; DRUG MANUFACTURE; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEALTH PROGRAM; HUMAN; MEDICAL SOCIETY; PATIENT SAFETY; PHARMACIST; PHARMACY; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; APPARATUS, EQUIPMENT AND SUPPLIES; ARTICLE; DRUG LEGISLATION; DRUG THERAPY; ECONOMICS; LEGAL ASPECT; PATIENT CARE;

DRUG INDUSTRY; DRUG THERAPY; EQUIPMENT AND SUPPLIES; HUMANS; LEGISLATION, DRUG; PATIENT CARE; PHARMACEUTICAL PREPARATIONS; PHARMACEUTICAL SERVICES; PRESCRIPTIONS, DRUG;

EID: 0642277766     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.15.1525     Document Type: Review

References (22)

1. Kracov DA. Legal issues and impact of restricted access and distribution. J Am Pharm Assoc. 2001; 41(6, suppl 1):S11-5.
2. American Society of Health-System Pharmacists. ASHP contacts FDA commissioner about pharmaceutical companies' restricted distribution systems. www.ashp.org/news/showArticle.cfm? id=1914 (accessed 2002 Nov 8).
3. Merck. Paget's patient support program. www.fosamax.com/fosamax/hcp/ patient/paget.html (accessed 2003 Feb 25).
4. Lotronex.com. Prescribing program for Lotronex. Pharmacist information, www.lotronex.com/pharminfo.htm (accessed 2002 Dec 11).
5. Food and Drug Administration. Lotronex information. www.fda.gov/cder/ drug/infopage/lotronex/lotronex.htm (accessed 2002 Oct 25).
6. Bayer Direct. Bayer direct program. Prolastin. www.bayerdirect.com/pro. htm (accessed 2002 Dec 5).
7. American Pharmaceutical Association. APhA letter on the impact of the Bayer Direct program for distributing Prolastin. www.aphanet.org/govt/prolastin. html (accessed 2002 Dec 5).
8. Actelion. Tracleer information. www. tracleer.com/tracleer_website/hcp/ home. asp (accessed 2002 Oct 25).
9. Food and Drug Administration. Subutex and Suboxone information page. www.fda.gov/cder/drug/infopage/subutex_suboxone/default.htm (accessed 2002 Nov 6).
10. Food and Drug Administration. Dear doctor letter. www.fda.gov/medwatch/ safety/2000/propull.htm (accessed 2002 Oct 25).
11. MICROMEDEX Healthcare series. Greenwood Village, CO: MICROMEDEX. Edition expired 2003 Mar.
12. Cada DJ, ed. Facts and comparisons. St. Louis: Facts and Comparisons; 2003: 947a, 948.
13. McEvoy GK, ed. AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists; 2002:2300.
14. Pfizer. Tikosyn resource center. www. tikosyn.com/(accessed 2002 Dec 11).
15. Food and Drug Administration. Accutane information page. www.fda.gov/cder/drug/infopage/accutane/default. htm (accessed 2002 Oct 25).
16. Drug Policy Alliance. Federal regulation of methadone treatment. www.soros.org/lindesmith/library/fedreg/fedreg5.html (accessed 2003 Feb 25).
17. Food and Drug Administration. Mifepristone information page. www.fda.gov/cder/drug/infopage/mifepristone/default.htm (accessed 2002 Oct 25).
18. Danco Laboratories. Mifeprex - the early option pill. www.mifeprex.com/ (accessed 2002 Dec 11).
19. Schering Corporation. PEG-Intron access assurance. www.access-assurance. com/ (accessed 2002 Dec 11).
20. Food and Drug Administration. Xyrem information page. www.fda.gov/cder/drug/infopage/xyrem/default.htm (accessed 2002 Oct 25).
21. Celgene. S.T.E.P.S. prevention and protection. www.celgene.com/steps/ index. htm (accessed 2002 Oct 25).
22. Food and Drug Administration. Questions and answers on trovafloxacin public health advisory. www.fda.gov/cder/news/trovan/qa.htm (accessed 2002 Dec 4).